Skip to main content
profile image for
  • Associate Professor, Center for Psychiatric Neuroscience, Feinstein Institutes for Medical Research
  • Director, Women’s Behavioral Health, Zucker Hillside Hospital, Northwell Health
  • Associate Professor, Psychiatry and Obstetrics & Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

About the investigator

Dr. Deligiannidis completed her undergraduate degrees in Biology and Psychology at the University of Massachusetts at Amherst. As a recipient of pre-doctoral Intramural Research Training Awards, she trained in molecular neuroendocrinology research at the National Institutes of Health (NIH). Dr. Deligiannidis completed additional research training at the NIH during medical school and residency in behavioral endocrinology and experimental therapeutics. She received her medical degree from, and completed her psychiatry residency and chief residency in psychopharmacology research at the University of Massachusetts Medical School. After residency she completed a visiting fellowship and further training in multimodal neuroimaging at the Massachusetts General Hospital/Martinos Center for Biomedical Imaging. 

Dr. Deligiannidis joined faculty at Zucker Hillside Hospital/Feinstein Institutes for Medical Research/Zucker School of Medicine at Hofstra/Northwell in September 2016 and is Board Certified by the American Board of Psychiatry and Neurology. Dr. Deligiannidis is the Director of Women’s Behavioral Health at Zucker Hillside Hospital. As a reproductive psychiatrist, she has expertise in treating women with mood and anxiety disorders linked to the menstrual cycle and pregnancy/postpartum periods. Her clinical practice is focused on pharmacotherapies for perinatal depression and anxiety. 

Over the past ten years, Dr. Deligiannidis has been a leader in the field of perinatal depression and in novel therapeutics research. Her research program includes a focus in psychoneuroendocrinology, particularly neurosteroids and hormones, and neuroimaging in women’s behavioral health. She has authored over 40 peer-reviewed articles plus several textbook chapters, has given over 60 oral presentations and presented over 70 research posters at scientific conferences. Dr. Deligiannidis has received federal, foundation and industry research funding. Her research efforts have been nationally recognized with many awards for research and for teaching of medical students and residents. Her research has been covered by major media outlets, including CNN, the Associated Press, National Public Radio, Boston Globe, Boston ABC News, Boston CBS News, CBS-New York, ABC-New York, Newsday and others.

Dr. Deligiannidis actively participates in national scientific committees and gives scientific presentations nationally and internationally. She is an Associate Member of the American College of Neuropsychopharmacology (ACNP), a member of the Anxiety and Depression Association of America (ADAA), the Society of Biological Psychiatry (SOBP), the American Society of Clinical Psychopharmacology (ASCP) and the Marcé Society of North America (perinatal mental health). She serves on the national ASCP Board of Directors, and the SOBP Executive Council, as a reviewer on over 20 scientific journals and on the Advisory Board for the journal Acta Psychiatrica Scandinavica. She also serves as a member of the ACNP Committee on Education & Training and actively serves as a federal grant reviewer for the Center for Scientific Review at NIH. 

Locally she serves on steering committees in both the Departments of Obstetrics & Gynecology and Psychiatry at Long Island Jewish Medical Center and Zucker Hillside Hospital and at the Katz Institute for Women’s Health on Long Island. She additionally serves on Faculty Council at the Zucker School of Medicine at Hofstra/Northwell.

Research focus

Dr. Deligiannidis’ interdisciplinary translational research incorporates her expertise in molecular neuroendocrinology, behavioral endocrinology, neuroimaging and depression clinical trials. She conducts translational research into the causes of peripartum depression and anxiety and conducts clinical trials of novel therapeutics. Her research focuses on the role of sex hormones and gender differences in depressive disorders and the effect of neuroactive steroids on neurochemistry and neurocircuitry in women. She is also a site investigator for an international perinatal psychiatry genetics consortium examining genetic risk factors for peripartum depression and postpartum psychosis. Her areas of research include:

  • Psychoneuroendocrinology (hypothalamic-pituitary-adrenal and gonadal axes, gonadal hormones and neuroactive steroids) in depression
  • Neuroimaging and neuroendocrine biomarkers of depression during times of reproductive change 
  • Gender differences in depression and treatment response
  • Neuroimaging (MRS, fMRI, DTI, EEG) in depression
  • Complementary and alternative/integrative treatments for depression

Education

University of Massachusetts Medical School (UMMS), Worcester, MA
Degree: Residency
2009
Field of study: Chief Residency in Psychopharmacology Research

University of Massachusetts Medical School (UMMS), Worcester, MA
Degree: Internship
2009
Field of study: Adult Psychiatry Residency Training Program

University of Massachusetts Medical School (UMMS), Worcester, MA
Degree: Internship
2005
Field of study: Adult Psychiatry Residency Training Program

University of Massachusetts Medical School (UMMS), Worcester, MA
Degree: MD
2004
Field of study: Clinical medicine

University of Massachusetts at Amherst, MA
Degree: BS
1997
Field of study: Biology/neuroscience

University of Massachusetts at Amherst, MA
Degree: BS
1997
Field of study: Psychology

University of Warwick, Coventry CV4 7AL, United Kingdom
1997
Field of study: Psychology and Neuropsychology

Honors & awards

  • 2019 Jennifer and Bradley Marsh Educational Advancement Award, Feinstein Institutes for Medical Research, Advancing Women in Science and Medicine
  • 2018 Katz Institute for Women’s Health – Partners Council for Women’s Health Research Innovation Grant
  • 2018 Innovation Award, Feinstein Institutes for Medical Research, Advancing Women in Science and Medicine
  • 2017-2019 NIH Extramural Clinical Research Loan Repayment Program Contract Competitive Renewal Award
  • 2017-2018 NIH Extramural Clinical Research LRP Award
  • 2017 Barbara Albinder Collaborative Women in Science Award, Feinstein Institutes for Medical Research, Advancing Women in Science and Medicine
  • 2013-2018 NIH K23 Career Development Award
  • 2016 SOBP George Thompson Award for Distinguished Service
  • 2014-2016 NIH Extramural Clinical Research LRP Award
  • 2014 NIH Early Career Reviewer, Center for Scientific Review
  • 2014 American College of Neuropsychopharmacology (ACNP) Travel Award
  • 2013 National Network of Depression Centers (NNDC) Annual Scientific Conference Travel Award
  • 2013 Early Career Achievement in Science and Health Award, UMass Medical School
  • 2012-2014 Career Development Institute (CDI) for Psychiatry Award, University of Pittsburgh/Stanford University
  • 2012 Faculty Teaching Award for Outstanding Resident Teaching, UMass Medical School Department of Psychiatry
  • 2011 UMass Medical School Center for Clinical & Translational Science (CTSA) Pilot Grant
  • 2011 UMass Medical School Faculty Scholar Award
  • 2011 Society for Biological Psychiatry (SOBP) Travel Scholarship Award
  • 2010 Worcester Foundation for Biomedical Research Grant
  • 2009 NIH/NIMH Resident Elective Program in Clinical Research, Behavioral Endocrinology Branch
  • 2009 NIH/NIMH Resident Elective Program in Clinical Research, Experimental Therapeutics/Pathophysiology Branch
  • 2009 NIMH/NCDEU New Investigator Award
  • 2008, 2009 APA/APIRE Junior Investigator Awards
  • 2007, 2008 American Society of Clinical Psychopharmacology/NIMH Clinical Trials in Psychopharmacology Awards
  • 1998-2000 NIH/NICHD Predoctoral Intramural Research Training Award, Developmental Endocrinology/Genetics/Neuroendocrine
  • 1996 NIH/NICHD Summer Intramural Research Training Award, Developmental Endocrinology/Genetics/Neuroendocrinology

Publications

  1. Frieder A, Fersh, M, Hainline R, Deligiannidis KM. (2019) Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. CNS Drugs, 33(3): 265-282.
  2. Deligiannidis KM, Fales CL, Kroll-Desrosiers AR, Shaffer SA, Villamarin V, Hall JE, Frederick BB, Sikoglu EM, Edden RAE, Rothschild AJ, Moore CM. (2019) Resting-state functional connectivity, cortical γ-aminobutyric acid and peripheral neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance and spectroscopy study, Neuropsychopharmacology, 44(3):546-554. 
  3. Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh A, Clemson C, Jonas J, Kanes S. (2018) Efficacy and safety of brexanolone iv, a GABAA receptor modulator, in women with postpartum depression: results from two double-blind, randomised, placebo-controlled phase 3 studies. Lancet, 392(10152):1058-1070.
  4. Reza N, Deligiannidis KM, Eustis EH, Battle CL. (2018) Complementary health approaches for treating perinatal depression. Obstetrics and Gynecology Clinics of North America, 45(3):441-454. 
  5. Buglione-Corbett R, Deligiannidis KM, Leung K, Zhang NN, Rosal M, Moore Simas TA. (2018) Expression of inflammatory cytokines across gestation in women with symptoms of perinatal depression, Archives of Womens Mental Health, 21(6):671-679.
  1. Silver M, Moore CM, Villamarin V, Jaitly N, Hall JE, Rothschild AJ, Deligiannidis KM. (2018) White matter integrity in medication-free women with peripartum depression: diffusion tensor imaging study using tract-based spatial statistics. Neuropsychopharmacology 43(7):1573-1580. 
  2. Kanes, S, Colquhoun, Gunduz-Bruce H, Raines, S, Arnold, R, Schacterle A, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffman E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S. (2017) Brexanolone (SAGE-547 injection) in postpartum depression: a randomised controlled trial. Lancet, 390 (10093):480-489. 
  3. Putnam KT, Wilcox M, Robertson-Blackmore E, Sharkey K, Bergink V, Munk-Olsen T, Deligiannidis KM, Payne J, Altemus M, Newport J, Apter G, Devouche E, Viktorin A, Magnusson P, Penninx B, Buist A, Bilszta J, O'Hara M, Stuart S, Brock R, Roza S, Tiemeier H, Guille C, Epperson CN, Kim D, Schmidt P, Martinez P, Di Florio A, Wisner KL, Stowe Z, Jones I, Sullivan PF, Rubinow D, Wildenhaus K, Meltzer-Brody S; Postpartum Depression: Action Towards Causes and Treatment (PACT) Consortium. (2017) Clinical phenotypes of perinatal depression are associated with time of symptom onset: Findings from an International Consortium, Lancet Psychiatry, 4(6):477-485.
  4. Kroll-Desrosiers A, Nephew BC, Babb JA, Guilarte-Walker Y, Moore Simas TA, Deligiannidis KM. (2017) Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year, Depression and Anxiety, 34 (2): 137-146.
  5. Deligiannidis KM, Kroll-Desrosiers A, Mo S, Nguyen HP, Svenson A, Jaitly N, Hall JE, Barton BA, Rothschild AJ, Shaffer SA. (2016) Differential peripartum plasma neuroactive steroid and GABA profiles in healthy women vs. women at-risk for developing postpartum depression, Psychoneuroendocrinology 70:98-107. PMCID: PMC4907817.
Read more

Related video